Company
lyell.com
The Future of Cell Therapy – Today
Also known as Lyell, Lyell Immunopharma, Inc.
- Status
- Operatingas of 2026-09-19
- Business model
- B2B
- Legal name
- Lyell Immunopharma, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer.
Funding snapshot
- Total raised
- $493MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $493M2020-03-05
Funding rounds
- Round, 2020
- $493M2020-03-05, SEC form D sold, 10 investors
Products
- Other
- LYL273
- Other
- rondecabtagene autoleucel, or ronde-cel
Loading relationship preview